Program
tanruprubart
Also written as “ANX005” and “Tanruprubart”.
Its studies are mostly in Guillain-Barre Syndrome · Huntington Disease · Anemia, Hemolytic, Autoimmune · Amyotrophic Lateral Sclerosis, led by Annexon.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Annexon | 71 open or running | phase 3since Jan 6, 2021 | Dec 21, 2016 | May 31, 2027phase 3 · NCT07020819 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2016First study: phase 1 study in Safety and Tolerability in Healthy VolunteersFirst studyNCT03010046 · 27 enrolled · Australia
- Jul 11, 2019Phase 1 study in Guillain-Barre SyndromeNCT04035135 · 14 enrolled · Bangladesh, Denmark
- Jul 27, 2020Phase 2 study in Huntington DiseaseNCT04514367 · 28 enrolled · United States
- Sep 23, 2020Phase 2 study in Amyotrophic Lateral SclerosisNCT04569435 · 17 enrolled · United States, Canada
- Dec 28, 2020Phase 2 study in Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570 · 7 enrolled · United States, Australia, Austria and more
- Jan 6, 2021Phase 3 study in Guillain-Barre SyndromeNCT04701164 · 242 enrolled · Bangladesh, Philippines
- Jun 6, 2025Phase 3 study in Guillain-Barre SyndromeNCT07020819 · 30 planned · United States, Denmark, France and more
Ahead
- May 31, 2027Primary completion: phase 3 study in Guillain-Barre SyndromeNCT07020819
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07020819Guillain-Barre Syndrome · United States, Denmark, France and more | 3 | Recruiting | May 31, 2027 | 30 |
| NCT04701164Guillain-Barre Syndrome · Bangladesh, Philippines | 3 | Completed | Apr 20, 2024 | 242 |
| NCT04691570Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Australia, Austria and more | 2 | Completed | Jan 17, 2023 | 7 |
| NCT04569435Amyotrophic Lateral Sclerosis · United States, Canada | 2 | Completed | Jan 10, 2024 | 17 |
| NCT04514367Huntington Disease · United States | 2 | Completed | Aug 29, 2022 | 28 |
| NCT04035135Guillain-Barre Syndrome · Bangladesh, Denmark | 1 | Completed | May 19, 2021 | 14 |
| NCT03010046Safety and Tolerability in Healthy Volunteers · Australia | 1 | Terminated | Jun 2018 | 27 |
How it is read
Names in the registry
- “ANX005”, 6 entries
- “Tanruprubart”, 1 entry
Conditions, from the studies’ own filings
- Guillain-Barre Syndrome, 3 studies
- Huntington Disease, 1 study
- Anemia, Hemolytic, Autoimmune, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.